Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Celgene

Status: Completed

Conditions: Lymphoma

Treatments: Drug: Revlimid

Study type: Observational

Funder types: Industry

Identifiers

NCT03098589

NIS-Celgene-JP-PMS-004

Details and patient eligibility

About

To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter referred to as relapsed or refractory Adult T-cell Leukemia Lymphoma (ATLL)).

1. Planned registration period 3 years
2. Planned surveillance period 4 years and 6 months after a month after the approval for partial changes in the approved items is granted for relapsed or refractory ATLL

Enrollment: 1,149 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Relapsed or Refractory Adult T-cell Leukemia Lymphoma

Exclusion criteria

• N/A

Trial design

1,149 participants in 1 patient group

Patients with T-cell leukemia lymphoma treated with Revlimid

Description:

Among patients with relapsed or refractory adult T-cell leukemia lymphoma, patients who received Revlimid will be targeted in this surveillance

Treatment:

Drug: Revlimid